Literature DB >> 3492178

Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.

I Luman, R W Wilson, R J Wallace, D R Nash.   

Abstract

We tested 231 isolates of Branhamella catarrhalis for beta-lactamase production and drug susceptibility by the National Committee for Clinical Laboratory Standards disk diffusion method. The nitrocephin disk (Cefinase) identified beta-lactamase in 98% of the enzyme-producing strains, and a zone diameter of inhibition of less than or equal to 29 mm for penicillin correctly predicted the presence of beta-lactamase in 99% of the isolates. No resistance to erythromycin, tetracycline, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanic acid was observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492178      PMCID: PMC176531          DOI: 10.1128/AAC.30.5.774

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Disc agar diffusion antimicrobial susceptibility tests with beta-lactamase producing Neisseria gonorrhoeae.

Authors:  J W Biddle; J M Swenson; C Thornsberry
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

2.  Identification and antimicrobial susceptibility testing of Branhamella catarrhalis in United States laboratories, 1983-1985.

Authors:  R N Jones; H M Sommers
Journal:  Drugs       Date:  1986       Impact factor: 9.546

3.  Branhamella catarrhalis.

Authors: 
Journal:  Lancet       Date:  1982-05-29       Impact factor: 79.321

4.  Acute maxillary sinusitis in children.

Authors:  E R Wald; G J Milmoe; A Bowen; J Ledesma-Medina; N Salamon; C D Bluestone
Journal:  N Engl J Med       Date:  1981-03-26       Impact factor: 91.245

5.  Evaluation of the rapid penicillinase paper strip test for detection of beta-lactamase.

Authors:  T R Oberhofer; D W Towle
Journal:  J Clin Microbiol       Date:  1982-02       Impact factor: 5.948

6.  beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid.

Authors:  T Farmer; C Reading
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

7.  Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid.

Authors:  G Ninane; J Joly; M Kraytman; P Piot
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

8.  Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis.

Authors:  G V Doern; K G Siebers; L M Hallick; S A Morse
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

9.  Branhamella (Neisseria) catarrhalis: criteria for laboratory identification.

Authors:  G V Doern; S A Morse
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

View more
  17 in total

1.  Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Authors:  S S Richter; P L Winokur; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Interpretation of gram-stained sputa containing Moraxella (Branhamella) catarrhalis.

Authors:  S M Ainsworth; S B Nagy; L A Morgan; G R Miller; J L Perry
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

3.  In vitro activity of BAY v 3522, a new cephalosporin for oral administration.

Authors:  T L Hodges; G M Eliopoulos; K Klimm; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

4.  Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

Review 5.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

6.  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.

Authors:  B A Brown; R J Wallace; C W Flanagan; R W Wilson; J I Luman; S D Redditt
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella catarrhalis.

Authors:  G V Doern; T Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

Review 9.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

10.  Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.

Authors:  H J Bootsma; H van Dijk; J Verhoef; A Fleer; F R Mooi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.